Carestream Dental vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Digital dental imaging and practice management software provider offering intraoral sensors, 3D imaging systems, and clinical software for dental practices and institutions worldwide.
About
Carestream Dental is a Rochester, New York-based provider of dental imaging technology and practice management software, operating as a business unit spun off from Carestream Health. The company offers a comprehensive portfolio of dental imaging solutions spanning intraoral X-ray sensors, panoramic imaging systems, 3D cone beam CT (CBCT) scanners, and the clinical software required to acquire, store, manage, and interpret dental images. Carestream Dental serves general dental practices, specialty clinics, dental schools, and group dental organizations globally.\n\nThe company's imaging software platforms, including CS Imaging and CS PracticeWorks, integrate clinical image management with practice workflow features such as patient scheduling, charting, and treatment planning. This integration between imaging hardware and software creates a vertically integrated ecosystem that encourages multi-product adoption within a single practice. Carestream Dental has built a significant installed base in North America and Europe over several decades of operation as part of larger parent organizations including Kodak and Carestream Health.\n\nCarestream Dental competes in the dental technology market against companies such as Dentsply Sirona, Planmeca, and Patterson Companies. The transition from film-based to digital radiography was a key growth driver historically, and the company now focuses on 3D imaging adoption, digital impression workflow integration, and cloud-connected imaging tools. Its deep roots in imaging hardware combined with proprietary software give it a bundled solution advantage when selling into practices upgrading their full radiography infrastructure.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.